Resources

Why ADHD Waiting Lists Are So Long in the UK and How We Compare Internationally

ADHD waiting times in the UK have grown dramatically. Adults and children alike can wait months or even years for assessment. Rising awareness, specialist shortages, and historical underfunding all contribute to the problem. This article explains the reasons for long queues, funding challenges, and how the UK compares internationally—with a touch of humor to keep you awake while reading.

Key Points

• NHS ADHD assessment demand has increased sharply since the pandemic
• Workforce shortages and a specialist-led model make it difficult to reduce waiting times
• Shared care with GPs can help, but it requires additional resources and funding
• Medicines supply is not the main constraint, and NICE negotiates cost-effective access
• UK health spending has historically lagged behind Europe, limiting capacity
•  

Demand Has Risen Faster Than Capacity

Referrals for ADHD assessment have skyrocketed, especially among adults. NHS England’s independent ADHD Taskforce reported that waiting times are “unacceptably long” and recommended support even before a formal diagnosis. You might wonder how this snuck up on us. After all, the UK spends vast sums on defence and scientific research. Surely someone could have foreseen that ADHD awareness would explode? Apparently not.

National Waiting-Time Standards Are Hard to Set

There is no England-wide target for ADHD waiting times. Data gaps and workforce shortages make it difficult to enforce national standards. Local regions fear that formal targets without sufficient staff or resources would simply highlight failings rather than improve access.

Workforce and Specialist Constraints

ADHD services are primarily consultant- and specialist-led. This specialist-centric model slows scaling and contributes to long waiting lists. One might joke that the NHS could hire donkeys to carry the paperwork if it helped reduce the staffing burden, but instead, they are experimenting with artificial intelligence. Enter Dr Computor, the new AI helping to triage and manage assessments, but sadly, no one has yet programmed it to make tea or give hugs. The Royal College of Psychiatrists has repeatedly described the delays as lasting years and has called for service expansion and better transparency.

Commissioning and Data Are Fragmented

Local variation in referral criteria, data collection, and service models makes it difficult to plan capacity or redirect resources efficiently. This fragmentation further entrenches backlogs across the country.

Shared Care Could Help If Properly Resourced

NICE recommends that after initial specialist titration, prescribing and monitoring move to primary care under shared-care agreements. This can free up specialist time for new assessments. However, this approach depends on GP capacity, administrative support, and stable agreements. Without sufficient staff and funding, shared care cannot fully solve the problem.

Medicines Supply Is Not the Primary Constraint

There were temporary supply disruptions for ADHD medicines such as methylphenidate, lisdexamfetamine, guanfacine, and atomoxetine from late 2023 into 2024. Availability has improved, and alternatives exist, but formulation switches can be clinically complex. Medicines supply has affected some patients but has not been the main driver of long queues. The NHS negotiates cost-effective access through NICE and commercial frameworks. This keeps the cost of medicines low, but it does not automatically free up the staff, time, or clinic space needed to assess more people. In short, the NHS is really careful with its pennies.

Funding Context Since the Blair and Brown Governments

Who remembers Tony Blair and Gordon Brown? Back in the early 2000s, NHS spending grew quickly in real terms, roughly six to seven percent per year, and the workforce expanded. Fast forward through all the recent “microwave” political terms, and you can count seven Prime Ministers since Blair: Blair, Brown, Cameron, May, Johnson, Truss, and Sunak. That is a lot of leadership changes to keep track of, almost like trying to follow a relay race where the baton keeps changing hands. The baton, once made of solid silver, is now just a hollow plastic shell, and experts are calling for a virtual fix to improve it. After 2010, real-terms growth slowed to about one to two percent annually, leaving the NHS with stretched resources. By 2022, the UK still spent less per capita on health than many European peers. In 2023, health spending was approximately 10.9 percent of GDP, but per-capita spending adjusted for purchasing power remained below most Western European countries.

International Comparisons

Europe: Workforce shortages and backlogs are common. Countries with established adult ADHD pathways, such as the Nordic nations, report better recognition and access. Others, including Ireland, experience long waits similar to the UK, often with a private-public two-tier system.

United States: Waiting lists are less formal because access is insurance-dependent, but evaluation demand has surged. Intermittent stimulant shortages since 2023 have created access constraints even when assessments are available.

Australia: A 2023 Senate inquiry highlighted fragmented ADHD pathways and long waiting times across states. Reforms are underway, but workforce and equity issues mirror the UK situation.

Bottom Line

Long ADHD waiting lists in the UK reflect demand growth colliding with a specialist-focused model and workforce and funding limitations. Shared care with GPs could release specialist capacity, but only with real investment in primary care and administrative support. Medicine supply is not the main bottleneck, but intermittent shortages have affected continuity. England is, metaphorically speaking, caught with its pants down. Durable progress needs clear data, realistic standards tied to staffing, expanded primary care involvement, and sufficient NHS funding.

Sources

• NHS England ADHD Taskforce Interim Report 2025 [link]
• Royal College of Psychiatrists Statements on ADHD Services [link]
• The King’s Fund, Mental Health Workforce and Capacity Reports 2025 [link]
• NICE Guideline NG87, ADHD Diagnosis and Management 2025 [link]
• Health Foundation and Institute for Fiscal Studies, NHS Funding Trends [link]
• OECD Health at a Glance, 2023 [link]
• MHRA and SPS ADHD Medicine Supply Alerts 2023-2024 [link]